| __timestamp | Blueprint Medicines Corporation | United Therapeutics Corporation |
|---|---|---|
| Wednesday, January 1, 2014 | 7890000 | 381287000 |
| Thursday, January 1, 2015 | 14456000 | 452612000 |
| Friday, January 1, 2016 | 19218000 | 316800000 |
| Sunday, January 1, 2017 | 27986000 | 330100000 |
| Monday, January 1, 2018 | 47928000 | 265800000 |
| Tuesday, January 1, 2019 | 96388000 | 336200000 |
| Wednesday, January 1, 2020 | 157743000 | 423900000 |
| Friday, January 1, 2021 | 195293000 | 467000000 |
| Saturday, January 1, 2022 | 237374000 | 487000000 |
| Sunday, January 1, 2023 | 295141000 | 477100000 |
| Monday, January 1, 2024 | 359272000 |
Igniting the spark of knowledge
In the competitive world of biotechnology, managing Selling, General, and Administrative (SG&A) expenses is crucial for maintaining profitability. United Therapeutics Corporation and Blueprint Medicines Corporation, two prominent players in the industry, have shown contrasting approaches over the past decade.
From 2014 to 2023, United Therapeutics consistently maintained higher SG&A expenses, peaking at nearly 480% more than Blueprint Medicines in 2014. However, Blueprint Medicines has seen a dramatic increase in their SG&A costs, growing by approximately 3,640% over the same period. This surge reflects their aggressive expansion and investment in new therapies.
While United Therapeutics' expenses have remained relatively stable, Blueprint Medicines' rising costs suggest a strategic shift towards growth. Investors and industry analysts should consider these trends when evaluating the financial health and strategic direction of these companies.
Gilead Sciences, Inc. vs United Therapeutics Corporation: SG&A Expense Trends
Operational Costs Compared: SG&A Analysis of United Therapeutics Corporation and Genmab A/S
United Therapeutics Corporation and Bio-Techne Corporation: SG&A Spending Patterns Compared
Breaking Down SG&A Expenses: United Therapeutics Corporation vs Lantheus Holdings, Inc.
SG&A Efficiency Analysis: Comparing United Therapeutics Corporation and Catalyst Pharmaceuticals, Inc.
Comparing SG&A Expenses: United Therapeutics Corporation vs Bausch Health Companies Inc. Trends and Insights
United Therapeutics Corporation vs Vericel Corporation: SG&A Expense Trends
United Therapeutics Corporation vs Xencor, Inc.: SG&A Expense Trends
Breaking Down SG&A Expenses: Ascendis Pharma A/S vs Blueprint Medicines Corporation
Breaking Down SG&A Expenses: Blueprint Medicines Corporation vs ACADIA Pharmaceuticals Inc.
SG&A Efficiency Analysis: Comparing Blueprint Medicines Corporation and Agios Pharmaceuticals, Inc.
SG&A Efficiency Analysis: Comparing Blueprint Medicines Corporation and Celldex Therapeutics, Inc.